View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AF16 | Publication ID: Fall 2003 |
Title: ●Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements, and Administrative Procedures; Derivatives of Blood | |
Abstract: FDA is proposing to amend the implementing regulation of the Prescription Drug Marketing Act of 1987, as modified by the Prescription Drug Amendments of 1992 and the FDA Modernization Act of 1997. The final rule (12/3/99; 64 FR 67720), does not allow a registered blood establishment that provides health care services related to its activities as a blood establishment to concurrently distribute derivatives of blood. The effective date of that rule is April 1, 2004. FDA is amending the final rule to allow a registered blood establishment that concurrently provides health care services to also distribute derivatives of blood. | |
Agency: Department of Health and Human Services(HHS) | Priority: Substantive, Nonsignificant |
RIN Status: First time published in the Unified Agenda | Agenda Stage of Rulemaking: Prerule Stage |
Major: Undetermined | Unfunded Mandates: No |
CFR Citation: 21 CFR 203.3(q) 21 CFR 203.22(h) 21 CFR 205.3(h) | |
Legal Authority: 21 USC 351 to 353 21 USC 371 21 USC 374 |
Legal Deadline:
|
||||||||
Overall Description of Deadline: Date final rule takes effect: “Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements, and Administrative Procedures." |
||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: Undetermined | Government Levels Affected: None |
Federalism: No | |
Included in the Regulatory Plan: No | |
Agency Contact: Kathleen E. Swisher Regulatory Counsel Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research, 1401 Rockville Pike, Suite 200N (HFM-10), Rockville, MD 20852 Phone:301 827-0372 |